Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
BELLINGS Intelligence Score: 8
Why it matters
Bank of America's spending on GLP-1 drugs for employees is a notable corporate health benefit disclosure but does not affect credit markets, underwriting, or systemic financial conditions.